Effectiveness of a Postal Intervention to Improve the Use of PPI
NCT ID: NCT03840018
Last Updated: 2019-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
401 participants
INTERVENTIONAL
2017-05-10
2018-04-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice
NCT00363701
Primary carE PPi dEprescRibing Trial
NCT05629143
Patient Journey Application for Discontinuing Inappropriate PPI Use: a Randomized Controlled Trial
NCT05348252
PPI and Microbiome in Healthy Volunteers and Functional Dyspepsia
NCT03545243
Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers
NCT00915239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main outcome variable was the number of active prescriptions of each PPI dose (high dose/standard dose/treatment cessation) at 6 months after the intervention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Sending doctors the lists of patients that meet the inclusion criteria to have their treatment reviewed
No interventions assigned to this group
Letter by post to patients
Patients were sent a letter explaining the risks of using PPIs at long-term high doses and encouraging them to visit their doctor
Letter by post to patients
Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Letter by post to patients
Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Osakidetza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elena Valverde
Primary care pharmacist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elena Valverde
Role: PRINCIPAL_INVESTIGATOR
Osakidetza
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bidasoa Integrated Health Organization
Hondarribia, Gipuzkoa, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EVB-IBP-2017-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.